BriaCell Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and has a $40.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Emily Bodnar’s rating is based on the promising clinical data from BriaCell Therapeutics’ Phase 3 Bria-ABC study, which indicates that their treatment, Bria-IMT, combined with checkpoint inhibitors, shows a significant improvement in progression-free survival (PFS) for patients with metastatic breast cancer who are DTH positive. The study’s results highlighted a statistically significant PFS benefit for DTH+ patients across all treatment arms, suggesting a potential advantage over the general patient population.
Additionally, the safety and tolerability profile of Bria-IMT remains favorable, with no serious adverse effects such as interstitial lung disease or CNS complications reported. The ongoing trial aims to conclude by the end of 2025, with a final analysis expected in 2026. The inclusion of various metastatic breast cancer subtypes and heavily pretreated patients further supports the robustness of the study, enhancing the potential for Bria-IMT to address unmet needs in this patient population.